高级检索
当前位置: 首页 > 详情页

Unfolded Protein Response Promotes Doxorubicin-Induced Nonsmall Cell Lung Cancer Cells Apoptosis via the mTOR Pathway Inhibition

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Biochemistry and Molecular Biology, Southwest Medical University, Luzhou, China [2]Department of Public Health, Southwest Medical University, Luzhou, China. [3]Department of Hepatobiliary Surgery of the Affiliated Hospital, Southwest Medical University, Luzhou, China. [4]Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu, China.
出处:
ISSN:

关键词: apoptosis doxorubicin NSCLC the UPR

摘要:
Drug resistance is extremely common in nonsmall cell lung cancer (NSCLC) and is one of the major problems in NSCLC chemotherapy. However, the detailed mechanisms remain largely unknown. Unfolded protein response (UPR) is involved in the tumorigenesis of NSCLC. Here, the authors demonstrated that the UPR promotes poly (ADP-ribose) polymerase activation (PARP) cleavage in NSCLC cells on doxorubicin treatment, which is a hallmark of apoptosis and caspase activation. In NSCLC cells, doxorubicin treatment triggers the UPR activation, which subsequently promotes doxorubicin-mediated apoptosis. Importantly, mild endoplasmic reticulum stress precondition enhances the sensitivity of NSCLC cells to doxorubicin-initiated apoptosis. Furthermore, the eukaryotic translation initiation factor 2 alpha (eIF2 alpha) branch of the UPR is involved in the synergistic role of the UPR in NSCLC cell apoptosis on doxorubicin treatment. They also demonstrated that the mTOR pathway plays an essential role in synergistic induction of apoptosis by the UPR and doxorubicin in NSCLC cells. Taken together, these results provide a potential mechanism that the UPR promotes doxorubicin-induced apoptosis in NSCLC cells, at least in part, by eIF2 alpha-mediated mTOR signal inactivation.

基金:

基金编号: 81472312 16TD0021 2013LZLY-J06 2015LZCYD-S01-8/15 2015LZCYD-S01-14/15 14JC0082 14JC0038

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学 4 区 药学 4 区 核医学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学 4 区 药学 4 区 核医学
JCR分区:
出版当年[2016]版:
Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q3 PHARMACOLOGY & PHARMACY Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 ONCOLOGY Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Biochemistry and Molecular Biology, Southwest Medical University, Luzhou, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Biochemistry and Molecular Biology, Southwest Medical University, Luzhou, China [4]Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu, China. [*1]Department of Biochemistry and Molecular Biology, Southwest Medical University No. 1 Xianglin Road, Luzhou 646000, China [*2]Department of Thoracic Surgery, Sichuan Cancer Hospital No. 55 South Section 4, Renmin Road, Chengdu 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号